Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Foxo3a expression is a prognostic marker in breast cancer.

Jiang Y, Zou L, Lu WQ, Zhang Y, Shen AG.

PLoS One. 2013 Aug 13;8(8):e70746. doi: 10.1371/journal.pone.0070746. eCollection 2013.

2.

FOXO3a nuclear localisation is associated with good prognosis in luminal-like breast cancer.

Habashy HO, Rakha EA, Aleskandarany M, Ahmed MA, Green AR, Ellis IO, Powe DG.

Breast Cancer Res Treat. 2011 Aug;129(1):11-21. doi: 10.1007/s10549-010-1161-z. Epub 2011 Feb 19.

PMID:
21336599
3.

Forkhead box transcription factor FOXO3a suppresses estrogen-dependent breast cancer cell proliferation and tumorigenesis.

Zou Y, Tsai WB, Cheng CJ, Hsu C, Chung YM, Li PC, Lin SH, Hu MC.

Breast Cancer Res. 2008;10(1):R21. doi: 10.1186/bcr1872. Epub 2008 Feb 29.

4.

Expression and prognosis of FOXO3a and HIF-1α in nasopharyngeal carcinoma.

Shou Z, Lin L, Liang J, Li JL, Chen HY.

J Cancer Res Clin Oncol. 2012 Apr;138(4):585-93. doi: 10.1007/s00432-011-1125-7. Epub 2011 Dec 31.

PMID:
22209974
5.

Increased expression of forkhead box M1 is associated with aggressive phenotype and poor prognosis in estrogen receptor-positive breast cancer.

Ahn H, Sim J, Abdul R, Chung MS, Paik SS, Oh YH, Park CK, Jang K.

J Korean Med Sci. 2015 Apr;30(4):390-7. doi: 10.3346/jkms.2015.30.4.390. Epub 2015 Mar 19.

6.

The estrogen receptor α is the key regulator of the bifunctional role of FoxO3a transcription factor in breast cancer motility and invasiveness.

Sisci D, Maris P, Cesario MG, Anselmo W, Coroniti R, Trombino GE, Romeo F, Ferraro A, Lanzino M, Aquila S, Maggiolini M, Mauro L, Morelli C, Andò S.

Cell Cycle. 2013 Nov 1;12(21):3405-20. doi: 10.4161/cc.26421. Epub 2013 Sep 17.

7.

Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.

Kim ST, Jeong H, Woo OH, Seo JH, Kim A, Lee ES, Shin SW, Kim YH, Kim JS, Park KH.

Am J Clin Oncol. 2013 Jun;36(3):224-31. doi: 10.1097/COC.0b013e3182467d90.

PMID:
22495453
8.

FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.

Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, Dunn S, Huntsman DG, Nakshatri H.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4415-21.

9.

Constitutively nuclear FOXO3a localization predicts poor survival and promotes Akt phosphorylation in breast cancer.

Chen J, Gomes AR, Monteiro LJ, Wong SY, Wu LH, Ng TT, Karadedou CT, Millour J, Ip YC, Cheung YN, Sunters A, Chan KY, Lam EW, Khoo US.

PLoS One. 2010 Aug 20;5(8):e12293. doi: 10.1371/journal.pone.0012293.

10.

FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.

Kawase M, Toyama T, Takahashi S, Sato S, Yoshimoto N, Endo Y, Asano T, Kobayashi S, Fujii Y, Yamashita H.

Breast Cancer. 2015 May;22(3):308-16. doi: 10.1007/s12282-013-0482-2. Epub 2013 Jun 16.

PMID:
23771556
11.

Decreased expression of the FOXO3a gene is associated with poor prognosis in primary gastric adenocarcinoma patients.

Yang XB, Zhao JJ, Huang CY, Wang QJ, Pan K, Wang DD, Pan QZ, Jiang SS, Lv L, Gao X, Chen HW, Yao JY, Zhi M, Xia JC.

PLoS One. 2013 Oct 23;8(10):e78158. doi: 10.1371/journal.pone.0078158. eCollection 2013.

12.

High scavenger receptor class B type I expression is related to tumor aggressiveness and poor prognosis in breast cancer.

Yuan B, Wu C, Wang X, Wang D, Liu H, Guo L, Li XA, Han J, Feng H.

Tumour Biol. 2016 Mar;37(3):3581-8. doi: 10.1007/s13277-015-4141-4. Epub 2015 Oct 11.

PMID:
26456958
13.

Expression and prognostic implications of FOXO3a and Ki67 in lung adenocarcinomas.

Liu HB, Gao XX, Zhang Q, Liu J, Cui Y, Zhu Y, Liu YF.

Asian Pac J Cancer Prev. 2015;16(4):1443-8.

14.

Expression of FOXM1 and related proteins in breast cancer molecular subtypes.

Lee JJ, Lee HJ, Son BH, Kim SB, Ahn JH, Ahn SD, Cho EY, Gong G.

Int J Exp Pathol. 2016 Apr;97(2):170-7. doi: 10.1111/iep.12187. Epub 2016 Jun 9.

15.

Decreased HCRP1 expression is associated with poor prognosis in breast cancer patients.

Xu J, Yang W, Wang Q, Zhang Q, Li X, Lin X, Liu X, Qin Y.

Int J Clin Exp Pathol. 2014 Oct 15;7(11):7915-22. eCollection 2014.

16.

High expression of FOXR2 in breast cancer correlates with poor prognosis.

Song H, He W, Huang X, Zhang H, Huang T.

Tumour Biol. 2016 May;37(5):5991-7. doi: 10.1007/s13277-015-4437-4. Epub 2015 Nov 23.

PMID:
26596836
17.

Prognostic value of bcl-2 expression among women with breast cancer in Libya.

Ermiah E, Buhmeida A, Khaled BR, Abdalla F, Salem N, Pyrhönen S, Collan Y.

Tumour Biol. 2013 Jun;34(3):1569-78. doi: 10.1007/s13277-013-0687-1. Epub 2013 Feb 16.

PMID:
23417836
18.

Prognostic significance of Bcl-2 in invasive mammary carcinomas: a comparative clinicopathologic study between "triple-negative" and non-"triple-negative" tumors.

Tawfik K, Kimler BF, Davis MK, Fan F, Tawfik O.

Hum Pathol. 2012 Jan;43(1):23-30. doi: 10.1016/j.humpath.2011.04.011. Epub 2011 Jul 20.

PMID:
21777944
19.

Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.

Kurebayashi J, Kanomata N, Yamashita T, Shimo T, Mizutoh A, Moriya T, Sonoo H.

Breast Cancer. 2015 May;22(3):292-9. doi: 10.1007/s12282-013-0478-y. Epub 2013 Jun 8.

PMID:
23749689
20.

TIF1γ interferes with TGFβ1/SMAD4 signaling to promote poor outcome in operable breast cancer patients.

Kassem L, Deygas M, Fattet L, Lopez J, Goulvent T, Lavergne E, Chabaud S, Carrabin N, Chopin N, Bachelot T, Gillet G, Treilleux I, Rimokh R.

BMC Cancer. 2015 Jun 4;15:453. doi: 10.1186/s12885-015-1471-y.

Supplemental Content

Support Center